AzTrials
AzTrials

OligomenorrheaNCT01927432

Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea

An observational study of Oligomenorrhea and Amenorrhea, run by Cornell University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
How many people
73 participants
Where
1 siteUnited States
Study dates
Sep 2011to Sep 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Study population: Women must be able to transport to Cornell University in Ithaca, NY. Eligible participants are between 18-35 years with a BMI of 18 kg/m2 or higher. Women are screened and enrolled following consent based on their response to our advertisements. Enrollment is restricted to the geographical area.

Who may be able to join

  • Between 18 and 35 years
  • BMI ≥ 18 kg/m2
  • If ≥ 21 years old, must have had healthy pelvic exam w/in past 2 years
  • Either:
  • Regular menstrual cycles (21-35 days);
  • Irregular menstrual cycles (>36 days) with or without a previous diagnosis of PCOS from a primary care provider

Who cannot join

  • Current use of medication(s) known or suspected to interfere with reproductive function (eg. oral contraceptives) or insulin sensitivity
  • Pregnant or breastfeeding
  • Not otherwise healthy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Human Metabolic Research Unit, Cornell University

    Ithaca, New York, 14853

Other trials in United States

About this study

In women with regular menstrual cycles, antral follicles have been shown to grow in synchronous cohorts, called waves, 2-3 times in a menstrual cycle. It is unknown whether these waves of follicle growth also occur in women with amenorrhea or if there is abnormal/absent follicle growth. Further, oligo- or amenorrhea has been associated with metabolic disturbances, such as over- or under-nutrition, central obesity and insulin resistance. Yet, mechanisms whereby metabolic factors influence folliculogenesis in women are poorly understood. To understand potential mechanisms, the investigators plan to characterize follicle growth dynamics in women with or without regular menstrual cycles and identifying key metabolic differences in these women which may be important in normal follicle development and fertility.

Read the detailed description

In the ovaries, eggs rest in fluid filled sacs called follicles. When follicles grow they form small fluid-filled cysts that can be easily seen when we use ultrasound to view the ovaries. In women with regular menstrual cycles, groups of 10 to 20 follicles grow and regress at 2 or 3 different times during their cycle (usually over a 28- day period). Several of these follicles grow to a stage where they begin to develop the potential to ovulate - but in general only one follicle is chosen to ovulate. Thus, at any given time during the menstrual cycle, numerous fluid-filled follicles can be visualized in a woman's ovaries at various stages of development using transvaginal ultrasonography. In women with absent or infrequent menstrual cycles, very little is known about the growth patterns of their follicles and how factors such as metabolic hormones, might play a role in the failure to ovulate. Being underweight or overweight increases your chances of having irregular or absent menstrual cycles and that a history of abnormal reproductive function compounds a woman's risk for chronic diseases such as infertility, diabetes, hypertension, atherosclerosis and certain cancers. This is particularly the case for women with polycystic ovary syndrome (PCOS) that have menstrual cycles that appear to worsen or improve depending on their body weight and metabolic status. PCOS is an endocrine disorder that affects 6-12% of reproductive-aged women within the general population. The hallmark features of PCOS are menstrual irregularity, increased levels of androgens, and polycystic ovaries. The current diagnostic criteria require 2 out of 3 of these features to be present for the diagnosis, therefore a number of phenotypes of PCOS exist. However, the metabolic and reproductive differences across the phenotypic spectrum of PCOS are not well understood. Women with PCOS characteristically have polycystic ovaries, where up to 10 times more follicles are present in the ovary at any given time. Further, the follicle-size populations and overall distribution throughout the ovary varies in women - follicles may be situated around the periphery of the ovary or may be distributed throughout the ovary. Presumably these small follicles are arrested in development - but emerging data from the Lujan laboratory suggest that this is not the case. It is assumed that ovulation does not occur and that follicles do not grow in a normal wave pattern. In truth, no study has ever looked to see whether follicles are actually growing, regressing or are arrested in women with irregular/absent menstrual cycles. By comparing follicle wave dynamics, reproductive hormones and markers of metabolism in women with regular and irregular menstrual cycles, the researchers plan to identify what factors might explain why fertility potential and long-term health are compromised in some women but not in others. Further, we will determine if any of these metabolic factors are unique to PCOS representing specific metabolic risks or follicle growth impairment. The ultimate goal of this research is to understand how body composition, nutrition and metabolism regulate follicle development in women so we can better develop lifestyle and drug therapies to help women preserve their fertility and long-term health. Since obesity has recently become the leading cause of infertility in North America, these studies are especially important.

To accomplish our objective, the investigators plan to recruit up to 40 women with regular menstrual cycles and up to 40 women with irregular/absent menstrual cycles. Our goal is to recruit an equal number of women in each group such that they are matched for age (18 - 35 years old) and body mass index (BMI; Normal weight = 18 - 24 kg/m2; Overweight = 25 - 29 kg/m2; Obese = 30kg/m2). Women will undergo serial ultrasonographic of their ovaries every other day from ovulation to ovulation in women with regular menstrual cycles or for 5 weeks in women with cycle irregularity. Blood samples will be collected at each visit. Ultrasound scans of the ovaries will be assessed for the total number, size, and distribution of follicles using ultrasound imaging techniques. Blood samples collected will be assayed to determine serum concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, progesterone, anti-müllerian hormone (AMH), and inhibin B. During day 3-5 in women with regular menstrual cycles or at a time where no dominant follicle or corpus luteum is present, an early morning visit will be conducted to assess the following metabolic parameters : (1) 75-gram oral glucose tolerance test to characterize glucose and insulin dynamics at 0, 30, 60, 90, and 120 minutes post-glucose ingestion; (2) dual X-ray absorptiometry (DXA) scan to quantify body fat and lean muscle distribution; (3) vitals and anthropometry assessment to measure waist and hip circumference, height, weight, blood pressure, and heart rate, and (4) fasting blood tests to detect serum concentrations of androgens (i.e., total testosterone, androstenedione, free androgen index) and serum markers of metabolic syndrome (i.e., lipids and hemoglobin A1C); (5) optional subcutaneous fat biopsy to analyze fat cells, which represent a site of reproductive hormone synthesis.

Keywords
Polycystic Ovary Syndrome (PCOS), Nutrition, Metabolism, Antral follicle growth, Menstrual Cyclicity
Medical subject headings
Oligomenorrhea, Amenorrhea, Polycystic Ovary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01927432
Study groupRoleWhat they receive
Regular menstrual cyclesAdult women will be assigned to this category if they report a history of regular menstrual cycles.
Irregular menstrual cyclesAdult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Follicle number

    The number of all antral follicles in each ovary will be determined using ultrasonography for each participant. Changes in follicle number over time will be compared between groups.

    Measured: 4-5 weeks

  2. Follicle diameter

    The diameter of all follicles >2mm will be determined using ultrasonography for each participant. Changes in follicle diameter over time will be compared between groups.

    Measured: 4-5 weeks

Secondary outcomes (16)
  1. Ovarian Volume

    The size of each ovary will be determined using ultrasonography for each participant during study participation and compared between groups.

    Measured: 4-5 weeks

  2. Anti-Müllerian hormone

    The serum AMH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Measured: 4-5 weeks

  3. Serum FSH concentration

    The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Measured: 4-5 weeks

  4. Serum LH concentration

    The serum FSH concentration will be determined during study participation and assessed in association with the change in follicle number, diameter and between groups.

    Measured: 4-5 weeks

  5. Serum progesterone concentration

    The serum progesterone concentration will be determined during study participation, assessed in association with luteal dynamics and compared between groups.

    Measured: 4-5 weeks

  6. LH-FSH ratio

    The ratio of circulating LH to FSH concentrations will be determined for each participant and compared between groups.

    Measured: 4-5 weeks

  7. Insulin sensitivity

    Insulin sensitivity will be determined by administration of an oral glucose tolerance test and compared between groups.

    Measured: 1 day

  8. Androgen concentrations

    Total testosterone, androstenedione and free androgen index concentrations in serum will be determined and compared between groups.

    Measured: 1 day

  9. Menstrual Cycle Length

    Average menstrual cycle length as determined by self-reported history and the menstrual cycle length during study participation will be determined and compared between groups.

    Measured: 4-5 weeks

  10. Hirsutism

    Degree of hirsutism as judged by the Ferriman-Gallwey scale will be determined and compared between groups.

    Measured: 1 day

  11. Serum markers of metabolic syndrome

    Lipids, glucose and HbA1C concentrations will be determined and compared between groups.

    Measured: 1 day

  12. Blood Pressure

    Blood pressure will be determined and compared between groups.

    Measured: 1 day

  13. Body mass index

    The ratio of weight to height will be determined and compared between groups.

    Measured: 1 day

  14. Waist-to-hip ratio

    The ratio of waist circumference to hip circumference will be determined and compared between groups.

    Measured: 1 day

  15. Body fat distribution

    Percentage and distribution of fat and lean mass as assessed using DXA technology will be compared between groups.

    Measured: 1 day

  16. Subcutaneous fat biopsy (optional)

    Fat cells, representing an important site of reproductive hormone production, will be compared between groups.

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Aug 2013 (estimated)
  2. Study startSep 2011
  3. Primary completionSep 2021
  4. Study completionSep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
73 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01927432
Sponsor's protocol ID
IRB #: 0908000633
Status last verified
Feb 2024
First submitted
20 Aug 2013
Last updated
9 Feb 2024
Results posted
No
Data monitoring committee
No

Publications

  • Evans AT, Rehani E, Smith B, Hong MD, Lewin Z, Hiroshige K, Spandorfer SD, Hajirasouliha I, Lujan ME, Hoeger KM. Diagnosis of Polycystic Ovary Syndrome With Predictive Modeling of Select Clinical Features. O G Open. 2026 Mar 19;3(2):e161. doi: 10.1097/og9.0000000000000161. eCollection 2026 Apr.

    PubMed 41868592
  • Oldfield AL, Carter FE, Reeves RE, Jarrett BY, Vanden Brink H, Lujan ME. Impact of a hypocaloric dietary intervention on antral follicle dynamics in eumenorrheic women with obesity. Hum Reprod. 2024 Apr 3;39(4):801-811. doi: 10.1093/humrep/deae017.

    PubMed 38335228
  • Oldfield AL, Vanden Brink H, Carter FE, Jarrett BY, Lujan ME. Obesity is associated with alterations in antral follicle dynamics in eumenorrheic women. Hum Reprod. 2023 Mar 1;38(3):459-470. doi: 10.1093/humrep/dead007.

    PubMed 36708012

Questions about this trial

What is this clinical trial studying?

An observational study of Oligomenorrhea and Amenorrhea, run by Cornell University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Follicle number (time frame: 4-5 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01927432, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in